Last edition
News about "Novo Nordisk"
Novo Nordisk Submits Updated Proposal to Acquire Metsera in Multi-Billion-Dollar Deal
Novo Nordisk has confirmed that it has submitted an updated, unsolicited proposal to acquire Metsera, which has been declared superior by Metsera’s board of directors.
Novo Nordisk | 06/11/2025 | By Dineshwori
Novo Nordisk Makes Unsolicited USD 6.5 Billion Bid to Acquire Metsera
Novo Nordisk, a leading global healthcare company founded in 1923 and headquartered in Denmark, has announced that it has submitted an unsolicited proposal to acquire Metsera, Inc.
Novo Nordisk | 01/11/2025 | By Darshana
FDA Approves Oral Semaglutide by Novo Nordisk for CV Risk Reduction in Adults with Type 2 Diabetes
Rybelsus (Semaglutide) tablets, available in 7 mg and 14 mg doses, is the only FDA-approved oral GLP-1 therapy, and is now indicated to lower the risk of Major Adverse Cardiovascular Events (MACE)—including CV death, heart attack, or stroke—in adults with type 2 diabetes at high cardiovascular risk.
Novo Nordisk | 21/10/2025 | By Dineshwori
Danish drugmaker Novo Nordisk has entered into a definitive asset purchase and license agreement with US-based Omeros Corporation for zaltenibart (formerly OMS906), a clinical-stage antibody therapy being developed for rare blood and kidney disorders.
Novo Nordisk | 16/10/2025 | By Dineshwori
Novo Nordisk to Acquire Akero Therapeutics Alongside Promising MASH Therapy Efruxifermin
Danish pharma giant Novo Nordisk has signed a definitive agreement to acquire Akero Therapeutics, a San Francisco-based clinical-stage biopharmaceutical company focused on developing innovative therapies for serious metabolic diseases.
Novo Nordisk | 10/10/2025 | By Dineshwori | 120
Novo Nordisk to Launch Ozempic in India
The once-a-week injectable, Ozempic will complement Novo Nordisk’s existing oral Semaglutide for diabetes and recently approved WeGovy for obesity.
Novo Nordisk | 30/09/2025 | By Dineshwori | 208
Wegovy (Semaglutide 2.4 mg) reduced risk of heart attack, stroke, or death by 57 percent when compared to Tirzepatide, and 29 percent across all patients, showing heart-protective benefits unique to the Semaglutide molecule.
Novo Nordisk | 19/09/2025 | By Dineshwori | 102
Novo Nordisk presented new findings from its Wegovy and Cagrilintide trials in obesity management at the ongoing European Association for the Study of Diabetes (EASD) 2025 congress in Vienna, Austria.
Novo Nordisk | 17/09/2025 | By Dineshwori | 175
Novo Nordisk to Cut 9,000 Jobs in Global Restructuring Amid Market Pressures
Novo Nordisk, the Danish pharmaceutical giant behind the weight-loss drug Wegovy and diabetes treatment Ozempic, has announced plans to cut 9,000 jobs worldwide—around 11 to 12 per cent of its workforce—as part of a major restructuring programme.
Novo Nordisk | 10/09/2025 | By Darshana
FDA tightens import controls on obesity drug ingredients amid safety concerns
The Food and Drug Administration (FDA) in the USA has intensified its scrutiny of imports containing GLP-1 drug ingredients, widely used in treatments for weight loss and diabetes, following increasing concerns over safety and quality.
Novo Nordisk | 06/09/2025 | By Darshana | 287
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy